Phase 1 Chronic Kidney Disease Trial, Recruiting NCT07045467 Sponsor: Qianfoshan Hospital Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 1 Chronic Kidney Disease Trial, Recruiting

NCT07045467
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have provided signed consent to participate
  • People aged 18 years or older but under 65 years
  • People with chronic kidney failure who are scheduled to receive a kidney transplant
  • People with a body mass index (BMI) between 18 and 30 (a standard measure of body weight relative to height)
  • People who weigh at least 50 kg (for males) or at least 45 kg (for females)
  • People whose overall physical health status is classified by a doctor as ASA III or IV — meaning they have a serious ongoing medical condition (confirm with trial site)

Who may not be able to join:

  • People who have liver disease, a psychiatric condition, or a neurological disorder
  • People who have a blood clotting disorder
  • People who have heart failure
  • People who have respiratory (breathing) failure
  • People who use sedatives or antidepressants on a long-term basis
  • People who are pregnant or breastfeeding
  • People who are unable to communicate or cooperate with trial requirements
  • People who have taken part in another drug or medical device trial within the past 3 months
  • People who test positive for hepatitis B
  • People who test positive for hepatitis C
  • People who test positive for HIV
  • People who test positive for syphilis
  • People who have taken certain medications that affect liver enzymes within the past 30 days (confirm with trial site for the specific list)
  • People with a known allergic or sensitivity reaction to two or more substances
  • People who have consumed more than 14 units of alcohol per week at any point in the 6 months prior to the trial
  • People with a history of drug abuse within the past 3 months
  • People who have had a major infection or serious physical injury within the past month
  • People who have had gastrointestinal (digestive tract) surgery that could affect how the body absorbs medication within the past month
  • People who have received a vaccine within the past month, or who plan to receive one during the study period
  • People who have lost or donated more than 400 mL of blood within the past 3 months
  • People who have received a blood transfusion within the past month
  • People whose blood clotting test results fall outside acceptable ranges (confirm with trial site)
  • People with a history of significant bleeding episodes within the past 3 months
  • People who are currently taking blood-thinning (anticoagulant) medication
  • People whom the trial investigator considers unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8618763995357

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Qianfoshan Hospital
Registry
ClinicalTrials.gov
Start date
1 July 2025
Est. completion
1 July 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Remimazolam Plasma Concentration; Remimazolam PK Parameters; Remimazolam PK Parameters; Remimazolam PK Parameters; Remimazolam PK Parameters; Remimazolam PK Parameters; Remimazolam PK Parameters; Remimazolam PK Parameters; Remimazolam PK Parameters; Remimazolam PK Parameters; Remimazolam PK Parameters; CNS 7054 (Metabolite) PK Parameters; CNS 7054 (Metabolite) PK Parameters; CNS 7054 (Metabolite) PK Parameters; CNS 7054 (Metabolite) PK Parameters; CNS 7054 (Metabolite) PK Parameters; CNS 7054 (Metabolite) PK Parameters; CNS 7054 (Metabolite) PK Parameters; Sedation Depth (PD); Time to Loss of...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov